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Abstract: Autophagy is an evolutionary conserved intracellular mechanism which helps eukaryotic
cells in maintaining their metabolic state to afford high-efficiency energy requirements. In the
physiology of a normal liver and the pathogenesis of liver diseases, autophagy plays a crucial
role. Autophagy has been found to be both upregulated and downregulated in different cancers
providing the evidence that autophagy plays a dual role in suppressing and promoting cell survival.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the major leading
cause of cancer mortality worldwide. In light of its high complexity and poor prognosis, it is essential
to improve our understanding of autophagy’s role in HCC. In this review, we summarize the dual
mechanism of autophagy in the development of HCC and elucidate the currently used therapeutic
strategies for anti-HCC therapy.
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1. Introduction
Autophagy (macroautophagy) is the fundamental cellular process in maintaining cell homeostasis
by targeting damaged intracellular organelles and misfolded proteins to lysosomal degradation [1].
It is a conserved evolutionary process that takes part in all mammalian cells under basal conditions
and generates building block molecules to support essential cellular processes [2]. Autophagy is a
multistep process including membrane rearrangement in forming a double-membrane bond structure
known as autophagosomes. The vesicle fusion of these autophagosomes with lytic compartments
generates autolysosomes where lysosomal enzymatic degradation of contents is recycled and releases
nucleotides, fatty acids, and amino acids to refuel the cells with energy to maintain necessary molecular
synthesis [2].
The role of autophagy is complex and differs from organ to organ. An organ such as muscles
and the liver requires autophagy to remove excessive protein aggregation, lipid accumulation, and
damaged mitochondria to prevent excessive ROS generation leading to oxidative stress [3,4]. Defects in
autophagy have shown to contributes in several pathogeneses of human diseases ranging from
neurodegenerative and metabolic diseases to cancers [5]. The dysregulation of autophagy has been
increasingly indicated to play a role in liver diseases such as alcoholic liver disease, non-alcoholic
fatty liver disease (NAFLD), hepatosteatosis, hepatomegaly, and primary liver malignancies such as
hepatocellular carcinoma (HCC) [6,7].
Hepatocellular carcinoma is a serious threat towards human health. It is the sixth most malignant
cancer worldwide and the fifth most common malignancy in men [8]. Despite recent advances in
treatments and surgical resection, the five-year survival rate remains unsatisfactory [9]. The most
common identified risk factors for HCC development are the consequences of unresolved oxidative
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stress, persistent inflammation, viral infections, metabolic dysfunction, liver alcohol disease, and fatty
liver disease. Autophagy may serve as a protective mechanism against the initial and persistent liver
injury in these disease states but autophagy may also play a significant role in the development and
growth of hepatic tumor cells in this inflammatory environment [10,11]. The link between autophagy
and cancer has been long proposed. The underlying mechanisms regulating the autophagic response
in HCC requires further understanding to develop effective treatment strategies.
2. Role of Autophagy in Normal Liver Homeostasis
Autophagy is involved in diverse physiology and pathophysiology of the liver. The liver
displays a complex metabolism with a variety of functions including protein and lipid synthesis
and secretion of bile acid. Increased accumulation of ubiquitin proteins aggregation observed
in the liver-specific Atg7 knockout mice suggested a basal function of autophagy in continuous
turnover of the cytoplasmic proteins [12,13]. Disturbance in the basal autophagy of the liver can
lead to the accumulation of elementary bodies, damaged mitochondria, deformed peroxisomes, and
abnormal membrane structures resulting in liver injury. Autophagy can be general and nonselective,
involving the degradation of a bulk cytoplasmic portion or organelle-specific degradation. The cell can
undergo different forms of autophagy which include xenophagy (degradation of viruses), lipophagy
(degradation of lipid droplets), ribophagy (degradation of ribosomes), pexophagy (degradation of
peroxisomes), reticulophagy (degradation of ER), and mitophagy (degradation of mitochondria).
Of these, mitophagy is one of the most well characterized since hepatocytes contain numerous
mitochondria to provide the high energy demand for metabolism. Liver specific autophagy deficient
mice provide evidence for swollen mitochondria and increased ROS formation [14]. Liver injury is
also associated with mitochondrial membrane permeabilization which can activate a mitochondrial
apoptotic pathway regulating BAX and Bad (BCL2 family) mediated cell death [15]. The different
forms and role of autophagy in the healthy liver are best described in detail by Takashi U Eno et al. [16].
Hepatocytes are primarily dependent on autophagy degradation due to its intense metabolism
and high energy demand to maintain proper functioning. The defect in any of the forms of autophagy
can contribute to severe liver functional damage such as hepatitis, fibrosis, cirrhosis, and HCC
development [17,18]. One of the most common causes of acute and chronic liver disease is the
infection of the liver with hepatotropic viruses. Hepatitis B and C viruses are both linked to the
autophagy. It has been shown that the X protein of the HBV (HBx) can induce autophagy due to its
ability to bind to the PI3k autophagic molecule. On the other hand, the Hepatitis C virus (HCV) can
adapt autophagy content to enhance its replication by inhibiting the maturation of autophagosome
into autophagolysosomes. Both these viruses are shown to induce autophagy by transcriptional
upregulation of Beclin1 [19].
Autophagy also plays a role in lipid metabolism and thus can influence the development of
fatty liver disease, a rapidly increasing cause of chronic liver disease in the world. Hepatocytes
are the main source for natural lipids stored in the form of triglycerides (TGs) and lipid droplets
(LDs). Interestingly, the first degradation of lipid droplets through lipophagy was observed in mouse
liver. It has been shown that ATg7 knockout mice showed significant increase levels of TGs and
LDs in the hepatocytes leading to a decrease in the levels of free fatty acids (FFAs), necessary for
ATP generation [20]. Another study illustrates the formation of hepatic steatosis in mice due to the
consumption of a high-fat diet. This process occurs through autophagy activation in hepatic stellate
cells and is due to the suppression of mTOR phosphorylation which increased expression of Sirt1
through the AMPK pathway [21].
3. Role of Autophagy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common primary cancer and a major leading cause of
death worldwide [22]. An estimation of 30,200 deaths is predicted this year [23]. The high proliferative
capability of HCC cells has been linked to persistent inflammation and increased oxidative stress.
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Autophagy has been shown to play a dual role in cancer. Autophagy could be either tumor suppressive
or tumor promoting. Here we review both the pro- and anti-tumor mechanism of autophagy that take
place during the development and growth of HCC.
3.1. Tumor-Suppressive Role of Autophagy
Inflammation is recognized as a hallmark of cancer in promoting tumor growth and is associated
with the poor prognosis of many solid tumors [24]. It is well known that HCC progression is highly
correlated with the persistent inflammatory stimulation [25]. Autophagy has been suggested to prevent
cancer progression by suppressing inflammation [26–29] while inhibition of autophagy can lead to a
sustained and elevated level of inflammation [30,31]. Inflammasomes are the major drivers for chronic
inflammation in the liver [32,33]. Interestingly, the capability of cells to suppress inflammation through
autophagy was first observed in autophagic inhibited mice. Lack of autophagic responses in ATG16L1
knockout mice undergoing septic shock revealed an elevated level of inflammasome associated IL-1β
and IL-18 cytokine production compared to wild-type controls [28]. Further studies showed that
depletion of the autophagic proteins, LC3B and Beclin1, enhanced Caspase-1 activation which was
NALP3 inflammasomes dependent. Mice lacking LC3B protein were more susceptible to LPS induced
mortality [34]. In addition, a recent study showed the effect of chemokine (C-X-C motif) ligand 17
(CXCL17) in suppressing autophagy [35]. In human HCC tissues, elevated expression of CXCL17 has
been observed which can also promote cell proliferation and migration when treated invitro. Silencing
of this induced autophagy which is due to the enhanced nuclear translocation of liver kinase b1 (LKB1)
that phosphorylates and activates AMPK. This lead to decrease in tumor volume and proliferation.
Beclin1, an important autophagic protein, has been shown to be associated with HCC tumors.
The decreased Beclin1 expression observed in human HCC tissues correlated with tumor recurrence
and disease-free survival [36]. Studies have also shown that knocking out Beclin1 in mice
is embryonically lethal whereas heterogeneous Beclin1 mice developed spontaneous HCC [37].
In addition, normal hepatocytes show higher expression and activity of autophagic-associated
proteins compared with HCC cell lines providing evidence that autophagy plays a tumor suppressive
role [14]. A recent study demonstrated the effect of adrenaline in promoting hepatocarcinogenesis [38].
Treatment of adrenaline in DEN-induced HCC mice showed a remarkable increase in liver injury
along with increased tumor number and tumor size. Mechanistically, increase in adrenaline
activated the adrenergic receptors ADRB2 which inhibited autophagy activation by disrupting the
Beclin1/VPS34/ATg14 complex.
Since autophagy plays a vital role in suppressing cancer inflammation, inhibition of autophagy
has also been shown to result in an excessive accumulation of p62 protein [39]. P62 is an autophagic
substrate which is used in measuring autophagic activity [40,41]. Transgenic P62 knockout animals
displayed irregular cell mitotic activity with an increased expression of insulin-like growth factor 2
(IGF2) in their HCC tumors [42]. It has been reported that p62 is necessary for the HCC initiation
by maintaining metabolic homeostasis through the mTOR pathway [43] and ablation of p62 inhibits
growth and proliferation [14]. In a study, 90 HCC-resected tumors were analyzed for the accumulation
of intracellular hyaline bodies (IHB) which are cytoplasmic inclusions consisting of p62. Patients with
increased IHB were shown to be associated with significantly shorter overall survival [44]. Moreover.
P62 is also known to interact with tumor necrosis factor receptor-associated factor 6 (TRAF6) that
induces nuclear factor (NF-kB) activation [45]. Zhang et al. [46] have shown that DEAD-box protein
5 (DDX5), a tumor suppressor protein in the liver [47], binds to p62 and interferes with P62/TRAF6
interaction. This results in autophagy induction. However, the expression of DDX5 in the human
HCC tumor tissues is relatively lower when compared to its non-tumor counterpart. Autophagy has
also been shown to contribute to the anti-proliferative activity of interferon gamma (IFN-gamma),
a pleiotropic cytokine that facilitates anti-viral and anti-proliferative effects in cancer cells. In HCC
cell lines, stimulated autophagosome formation inhibited cell growth. Silencing of autophagy in these
cells abolished the inhibitory effect, suggesting an essential anti-tumorigenic activity [48].
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Similarly, multiple miRNAs which are found to target autophagic comprised genes for autophagy
modulation [49–51] may also play a part in HCC growth and inhibition. miR-7 is a well acknowledged
tumor suppressive microRNA in cancers. In HCC tumors, levels of miR-7 are significantly
downregulated. It has been shown that upregulation of miR-7 in HCC cell lines increases autophagic
activity by targeting the mTOR pathway, leading to a decrease in cancer cell proliferation [52]. miR-85 is
an essential component during liver development and has also been linked as a tumor suppressor in
HCC. In human HCC cell line HepG2, transfection of miR-85 upregulated autophagic activity which
resulted in cell cycle arrest [53]. Our group has also previously shown that miR-375 is downregulated
in HCC cell lines and tissues [54]. We found that miR-375 inhibits autophagy by suppressing the
conversion of LC3I to LC3II by downregulating ATG7. Inoculating miR-375 overexpressed cells in
nude mice showed significantly decreased tumor growth [51].
3.2. Tumor-Promoting Role of Autophagy
Hypoxia-induced oxidative stress is one of the most prominent features in all solid tumors [55,56]
due to the inadequate blood supply that tumors experience as they grow. Under oxygen deprivation,
cells respond by regulating their metabolic and bioenergetics demands to overcome the hypoxic
resistance [57–59]. Hypoxia-induced autophagy in hepatocytes and HCC tumor cells relies upon the
stabilization of hypoxia-inducible factor (HIF1α). HIF is the important regulator that maintains oxygen
homeostasis. It has been shown that HIF1-α upregulates BNIP3 and BNIP3L proteins which binds to
the BCL-2 protein. This process inhibits the disruptive interaction between BCL-2 and Beclin1 [60]
to induce autophagy for cellular survival in hypoxic conditions. In addition, hypoxia is also shown
to upregulate early growth response gene-1 (Egr-1) expression. Egr-1 is a zinc finger nuclear protein
and functions as a transcriptional regulator [61]. Upregulation of hypoxia induced Egr-1 has shown to
induce autophagy in HCC cell lines promoting migration. Inhibiting Egr-1 function by Ad-DN-Egr-1
revealed the attenuated autophagosome formation due to inhibited binding of Egr-1 at LC3 promoter
region (−233 to −214) [62].
The extensive reactive oxygen species generation during the developing tumor is the primary
outcome of hypoxic stress. Increased ROS levels are shown to oxidize cellular components such as
DNA, lipids, and proteins [63,64]. ROS can be generated by the NADPH oxidase complexes in the cell
membrane, endoplasmic reticulum, peroxisomes, and mitochondria [65,66]. Tumors adapt different
mechanisms to eliminates intracellular ROS, one of which is by the upregulation of anti-oxidant
proteins NRF2 [67]. NRF2 is a cytoplasmic protein which translocates to the nucleus for the
transcription of redox-balancing proteins and β-oxidant enzymes and is upregulated by autophagy.
The autophagic protein p62 has been shown to interact with NRF2 [68]. Phosphorylated p62 binds with
Keap1 (NRF2 inhibitory protein) allowing NRF2 release and cytosolic stabilization [69,70]. The clinical
implication of NRF2 was elucidated in 107 HCC patients where patients that expressed higher levels
of pNRF2 were significantly associated with worst disease-free survival and poor overall survival [71].
Thus, p62 induces the antioxidant activation pathway to prevent extreme organelle injury leading to
tumor cell death.
Another important mechanism to control excess ROS production is by the removal of damaged
organelles from the cell. Injured and non-functional mitochondria are the major source of cellular
ROS production and the induction of mitophagy helps clear these damaged mitochondria to
maintain cell function and bioenergetics [72,73]. Mitochondrial ROS is eliminated regularly by the
superoxide dismutase within the cytosol [74,75] which is also activated by the NRF2 protein [76].
Depolarized mitochondria cleared via mitophagy are regulated by PINK1 and Parkin1 [77]. It is
reported that mitophagy can degrade tumor suppressor p53 once localized to mitochondria and inhibit
its subcellular localization. Mitophagy impairment results in p53 accumulation and its phosphorylation
by PINK1 prevent hepatic cancer cell stemness [78]. However, excessive induction of mitophagy can
also inhibit HCC migration. When yes-activated protein (Yap), a highly upregulated protein in
HCC, is depleted, mitophagy is overactivated leading to cellular energy deprivation [79]. In contrast,
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the excessive activation of autophagy may also lead to autophagic cell death [80,81]. This process
requires an additional cell death signaling, including the phosphorylation of c-Jun N-terminal kinase
(JNK) [82]. Interestingly, the pro-apoptotic (Bax/Bak) deficient cells showed an autophagic cell
death when exposed to apoptotic stimuli. This was driven through the increase in the level of JNK
phosphorylation. However, treatment with the JNK inhibitor further revealed that a simultaneous
activation of autophagy and JNK is required for the autophagic cell death. Numerous other cell
death and tumor suppressor-related proteins are shown to trigger autophagic cell death in the
literature [83–85].
Autophagy can also regulate inflammatory immune response by the release and degradation
of damage associated molecular patterns (DAMPS) including high mobility group box 1 (HMGB1),
histones, ATP, mitochondrial (mt)DNA, and mitochondrial transcription factor A (TFAM). HMGB1 is
a well-characterized DAMP which can be released from necrotic or apoptotic hepatocytes [86,87].
Interestingly, autophagy-mediated intracellular mobilization of HMGB1 enables tumor growth by
inducing cell survival and apoptosis [88,89]. We have previously shown that under hypoxic stress,
HMGB1 translocates from nucleus to cytoplasm in HCC cells. Intracellular translocation of HMGB1
facilitates its interaction with mtDNA in the cytosol where together they activate TLR9 signaling
pathways to enhance tumor growth [90].
3.3. Autophagy in HCC Metastasis
Autophagy, due to its tumor promoting role, also plays a part in tumor metastasis. Increasing
evidence suggests the upregulation of autophagy during the process of tumor metastasis [91,92]. As the
primary tumor grows and encounter harsh microenvironment, part of it escapes and intravasates
within the circulatory and lymphatic system, localizing at distal organs [93]. Cell detachment from the
extracellular matrix (ECM) has demonstrated to trigger autophagy which then protects it from anoikis,
a type of cell death induced in response to ECM detachment [94]. In addition, Autophagy can also
induce changes in the cell adhesion signaling that facilitates invasion and migration [95].
Autophagy in hepatocellular carcinoma has shown to facilitate metastasis by upregulating the
expression of epithelial–mesenchymal transition (EMT). Induction of autophagy in the starved cells
inhibited the expression of epithelial markers and induced mesenchymal expression along with cell
invasion marker matrix metalloproteinase-9 (MMP9) [96]. These changes were regulated by the
activation of TGF-beta and phosphorylation of Smad3 signaling pathway. In another study, inhibition
of autophagy via silencing Beclin1 and ATG5 in HCC lung metastasis model markedly decreased
distal metastasis to the lungs [97]. This effect is observed due to the impaired anoikis resistance that
can suppress the colonization of HCC cells. However, silencing of autophagy mediators showed no
effect in the expression of cell migration and invasion regulators.
Autophagy-mediated cancer cell metastasis can be stimulated by numerous stress factors
persisting within the tumor microenvironment. One of which is the fluid shear stress (FSS).
Wang et al. [98] showed that HCC cells, when exposed to 1.4 dyn/cm2 of FSS, induce autophagy
in a time-dependent manner. Furthermore, inhibition of autophagy attenuated cells to migrate and
downregulate the expression of PI3K/FAK/Rho GTPase pathway. This suggests that the activation of
autophagy via FSS is a PI3K/FAK/Rho GTPase-dependent pathway.
4. Autophagy in HCC Therapy
As described above, autophagy can be either be pro- or anti-tumorigenic for HCC. Therefore,
modulation of autophagy-based HCC therapy is very complex and will vary depending on the setting.
Autophagy can suppress liver inflammation and thus decrease the carcinogenic environment in the
liver but it can also promote and maintain tumor cell homeostasis by inducing mitophagy in growing
HCC tumors. In addition, both the induction and inhibition of autophagy has been investigated to
induce tumor cell death [99,100]. Currently, there are a variety of therapeutic agents that are being
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used either individually or in combination with other agents for anti-HCC therapy. The current agents
used to selectively target autophagy to induce HCC cell death are described in Table 1.
4.1. Autophagy Inducers
The autophagy inducer sorafenib is the first-line drug used for the treatment of advanced
HCC [101]. Currently, sorafenib is the only drug that has been shown to improve HCC patient
survival [102]. In a randomized controlled trial, patients with advanced HCC treated with sorafenib
had an improved rate of overall survival compared to patients given placebo. Sorafenib has been
shown to promote cell death through the upregulation of autophagy via myeloid cell leukemia-1
(Mcl-1) signaling pathway [103]. In addition, sorafenib can also inhibit tumor growth by targeting
the RAF/MEK/ERK pathway to induce cell cycle arrest [104]. Besides Mcl-1 and ERK pathways,
sorafenib can also inhibit the activation of PI3K/AKT/mTOR pathways which initiates a signaling
cascade for autophagy induction [105,106]. In a recent study, sorafenib is also shown to regulate cell
endoplasmic reticulum (ER) stress, JNK, Akt, and AMPK pathway leading to elevated autophagy
which later shifts towards apoptosis [107]. At an early time point (3–12 h) sorafenib increases ER stress
which is shown to induce the autophagic survival process in HCC cell line by regulating JNK/AMPK
signaling pathway. At a later stage (24 h), a significant increase in the ER stress and PERK-CHOP
dependent rise of Bim shifted autophagy to apoptosis cell death.
Besides its tumor suppressing function, long term sorafenib treatment has also shown to trigger
chemo-resistance in HCC cells [108]. Thus, the combination of sorafenib with SAHA, another
autophagy-inducer, has been used to improve responses against HCC compared to treating with
sorafenib alone [109]. Sustained treatment of sorafenib has also shown to increase tumor hypoxic
environment that leads to decrease treatment efficiency [110]. Combination of melatonin with sorafenib
has shown to enhance sorafenib’s cytotoxicity against human HCC cells by decreasing hypoxic
resistance [111]. Co-administration diminished the expression of BNIP3 and NIX, hypoxia induced
mitophagy mediators. Due to the common occurrence of tumor resistance, the combinations of different
drugs with sorafenib are currently being studied to increase chemo-sensitivity and decrease tumor
growth. A detailed combination of reagents with sorafenib are extensively reviewed elsewhere [112].
4.2. Autophagy Inhibitors
Since autophagy can be utilized by the growing cancer cells for its survival and add resistance
towards chemotherapeutic reagents, inhibiting autophagy can also be a promising strategy against
cancer therapy. At present chloroquine (CQ), an anti-malarial drug, can be used for the inhibition of
autophagy through the suppression of lysosomes. Treatment with CQ neutralizes the pH levels of
lysosomes required in the final stages of autophagy for degradation [113]. CQ is being effectively used
in patients with the combination of drugs capable of inducing cell apoptosis such as oxaliplatin [114].
It is reported that co-treatment of proliferative HCC cell lines with CQ and sorafenib can lead to a
marked suppression of its growth [105]. In a liver xenograft tumor model, nude mice treated with
CQ and sorafenib combined achieved a higher level of tumor regression compared to treatment with
sorafenib alone. In addition, 3-methyladenine (3-MA) which inhibits the interaction of autophagosomes
and lysosomes can enhance anti-HCC therapy when combined with cisplatin, doxorubicin, and
sorafenib [115]. Similarly, suppression of autophagy by administration of 3-MA and inactive ATg4B
suppresses the proliferation of Huh7 cells [116]. Hence, inhibition of autophagy can promote the death
of HCC cells but these treatments with their known side effects highlight a major risk in triggering the
neoplasticism within the normal hepatocytes.
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Table 1. Therapeutic reagents modulating autophagy in anti-HCC treatment.










(RAD001) mTOR Hep3B, HepG2, Huh7
Upregulation of
autophagy-cell death [120]
Pemetrexed mTORC1 HepG2 Upregulation ofautophagy-cell death [121]
SC-59 mTORC1 PLC5, Sk-Hep1, HepG2 andHep3B
Upregulation of
autophagy-cell death [122,123]
BEZ235 PI3K/mTOR Hep3B, PLC/PRF/5 Upregulation ofautophagy-cell death [124]
MK-2206 AKT SNU449, SNU378, SNU475 Upregulation ofautophagy-cell death [125]
SB203580 MAPK HepG2, Hep3B, PLC/PRF/5,Huh-7
Upregulation of
autophagy-cell death [126]
Regorafenib Tyrosine-kinaseinhibitor HepG2 and Hep3B
Upregulation of
autophagy-cell death [127]
Sorafenib Tyrosine-kinaseinhibitor Hep3B, HepG2, Huh7
Upregulation of
autophagy-cell death [105,112]
Nilotinib Tyrosine kinaseinhibitor PLC5, Huh-7, Hep3B
Upregulation of
autophagy-cell death [128]
ABT-737 JNK pathway Huh7, HepG2 Upregulation ofautophagy-cell death [129]
OSU-03012 PDK1/AKT Huh7, Hep3B, and HepG2 Upregulation ofautophagy-cell death [130]








Chloroquine Lysosome HepG2, Huh7, HA22T/VGH,Mahlavu
Downregulation of
autophagy-cell death [132,133]









Autophagy is the vital response for hepatocytes undergoing stress in the maintenance of cellular
homeostasis and quality control. As we outlined in this review, evidence supports a dual role of
autophagy in the progression of HCC (Figure 1). Targeting autophagy can be used to treat liver cancer.
However, caution should be noted as autophagy can inhibit the development of HCC but also act
as a tumor promoter resulting resistance to HCC tumor therapy [137]. Multiple direct and indirect
interactions including complex mechanistic overlap between apoptotic and autophagic cell death have
been studied [138,139]. Many studies indicate that the apoptotic events alter autophagy. However, the
molecular role of autophagy controlling apoptosis requires further investigation. In the developing
tumor microenvironment, hypoxia is a common stimulus in many cancers and hepatotropic viruses
can induce a hypoxic environment initiating hypoxic oxidative and inflammatory responses [140].
Thus improving tumor oxygenation or suppressing hypoxia-induced autophagy signaling could be a
potential future therapeutic pathway to target. We currently have a minimal understanding regarding
the stress signaling that takes part in the complex coordination of autophagy to respond during
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different intracellular and extracellular stimuli in HCC. Additional studies are necessary to further
elucidate the mechanisms underlying autophagy’s role in HCC.Cells 2019, 8, x 8 of 15 
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